Cargando…
Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334491/ https://www.ncbi.nlm.nih.gov/pubmed/35749011 http://dx.doi.org/10.1007/s40121-022-00660-6 |
| _version_ | 1784759114792960000 |
|---|---|
| author | Yang, Joe Naik, Jaesh Massello, Matthew Ralph, Lewis Dillon, Ryan James |
| author_facet | Yang, Joe Naik, Jaesh Massello, Matthew Ralph, Lewis Dillon, Ryan James |
| author_sort | Yang, Joe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9334491 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93344912022-07-30 Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms Yang, Joe Naik, Jaesh Massello, Matthew Ralph, Lewis Dillon, Ryan James Infect Dis Ther Correction Springer Healthcare 2022-06-24 2022-08 /pmc/articles/PMC9334491/ /pubmed/35749011 http://dx.doi.org/10.1007/s40121-022-00660-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Yang, Joe Naik, Jaesh Massello, Matthew Ralph, Lewis Dillon, Ryan James Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms |
| title | Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms |
| title_full | Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms |
| title_fullStr | Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms |
| title_full_unstemmed | Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms |
| title_short | Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms |
| title_sort | correction to: cost-effectiveness of imipenem/cilastatin/relebactam compared with colistin in treatment of gram-negative infections caused by carbapenem-non-susceptible organisms |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334491/ https://www.ncbi.nlm.nih.gov/pubmed/35749011 http://dx.doi.org/10.1007/s40121-022-00660-6 |
| work_keys_str_mv | AT yangjoe correctiontocosteffectivenessofimipenemcilastatinrelebactamcomparedwithcolistinintreatmentofgramnegativeinfectionscausedbycarbapenemnonsusceptibleorganisms AT naikjaesh correctiontocosteffectivenessofimipenemcilastatinrelebactamcomparedwithcolistinintreatmentofgramnegativeinfectionscausedbycarbapenemnonsusceptibleorganisms AT massellomatthew correctiontocosteffectivenessofimipenemcilastatinrelebactamcomparedwithcolistinintreatmentofgramnegativeinfectionscausedbycarbapenemnonsusceptibleorganisms AT ralphlewis correctiontocosteffectivenessofimipenemcilastatinrelebactamcomparedwithcolistinintreatmentofgramnegativeinfectionscausedbycarbapenemnonsusceptibleorganisms AT dillonryanjames correctiontocosteffectivenessofimipenemcilastatinrelebactamcomparedwithcolistinintreatmentofgramnegativeinfectionscausedbycarbapenemnonsusceptibleorganisms |